Objective: The present study aimed to develop a food for special medical purposes (FSMP) and to assess its efficacy as adjuvant therapy in patients with chronic hepatitis C virus (HCV). Design: Open randomized clinical trials with a tomato-based FSMP used as adjuvant treatment to the pharmacological therapy with pegilated interferon and ribavirin. Subjects: Eight healthy volunteers and 39 HCV patients. Interventions: For the bioavailability study, healthy subjects consumed 100 g/die FSMP for a week and their serum carotenoid profile at baseline, after the week of administration and 7 days later was determined. The same quantity of FSMP for 6 months by 20 of the 39 HCV patients was consumed in the clinical trial. Serum transaminase, haemoglobin (Hb) and hydroperoxide concentrations during the therapy were monitored in all patients. Results: FSMP consumption caused a fourfold increase of lycopene serum concentration in healthy subjects. A significant increase of carotenoids after 1 month of consumption also in patients with HCV was recorded. Transaminase and Hb serum levels, as well as therapeutic response, were not influenced by FSMP. The decrease in serum hydroperoxides was independent from FSMP consumption in long-term responder patients, whereas nonresponder (NR) patients of FSMP group showed higher reductions than NR patients of Control group. Conclusions: The FSMP was effective in improving carotenoid status in healthy subjects. In HCV patients, it did not influence the therapeutic response, but it prevented carotenoid serum depletion and it was effective in improving the oxidative status during antiviral therapy in NR patients.
Introduction
Many epidemiological studies demonstrated an inverse correlation between tomato consumption and the risk of some digestive tract cancers (Franceschi et al., 1994) , as well as lycopene intake and risk of prostate cancer (Giovannucci et al., 1995) and myocardial infarction (Kohlmeier et al., 1997) . Since it was widely reported that lycopene serum concentration was significantly lower in subjects who developed pancreatic (Burney et al., 1989) and bladder cancer (Helzlsouer et al., 1989) or cervical intraepithelial neoplasia (VanEenwyk et al., 1991) , it was hypothesized that this compound exerted a protective effect owing to its antioxidant properties (Di Mascio et al., 1991; Miller et al., 1996; Rice-Evans et al., 1997) .
The in vivo physiological effects of carotenoids are related to their bioavailability. Carotenoids, incorporated into mixed micelles, are absorbed by the mucosa of the small intestine. Transported to the serosal side, they are packaged in chylomicrons and secreted in the thoracic duct. Hepatocytes incorporate most of the carotenoids into lipoproteins, which are then released into the systemic circulation.
Many 'dietary' and 'lifestyle' factors modulate carotenoid bioavailability. The co-ingestion of fats and the type of dietary fats, as well as the contemporary consumption of dietary fibres or the heat treatment of carotenoid-containing foods, might influence the absorption of these compounds.
Heat treatment increases carotenoid bioavailability favouring the disruption of chemical structures formed by carotenoids and other food components, as well as converting some all-trans carotenoids to cis-isomers, apparently better incorporated into the mixed micelles (Levin et al., 1994) .
Fats increase carotenoid bioavailability, favouring, in the stomach, carotenoid extraction from food matrix and stimulating, in the upper gut, the excretion of biliary acids, the consequent formation of chylomicrons and therefore qthe absorption of all lipophilic phytochemicals (Erdman et al., 1993) .
The type of oil added to fresh tomatoes before consumption was also hypothesized to influence the carotenoid bioavailability, the antioxidant activity of the tomato sauce, as well as the antioxidant status of administered subjects (Hu et al., 2000; Fielding et al., 2004) . In particular, phenolic compound-rich oils, such as extra-virgin olive oil, increase carotenoid absorption, thanks to the protection exerted by polyphenols towards tomato carotenoids during heat treatment (Graziani et al., 2003) .
The relationship between oxidative stress and the induction and/or progression of all types of liver damage is widely recognized. Therefore, many therapeutic intervention with antioxidant compounds have been proposed (Loguercio et al., 1996; Peterhans, 1997; Jones and Czaja, 1998; Jakus and Lopuchova, 1999; Kaplowitz, 2000; Mori and Hirayama, 2000; Par et al., 2000; Schlenker et al., 2000) . Extracts from Sylibum marianum, Salvia milthiorriza, Psyllantus amarum and glutathione, S-adenosylmethionine, sylimarin, vitamin E, Nacetyl-cysteine, ursodeoxycholic acid have been proposed in the treatment of viral and alcoholic liver diseases (Houglum et al., 1997; Ott et al., 1997; Von Herbay et al., 1997; Flora et al., 1998; Kaiano et al., 1998; Pares et al., 1998; Wasser et al., 1998; Mato et al., 1999; Mitsuyoshi et al., 1999; Shuppan et al., 1999) in combination with the pharmacological treatment.
In particular, the supplementation with a-tocopherol is the most common dietary integration in the management of liver diseases, but the efficacy of antioxidant supplementation as pure compounds is still controversial. Literature data reported that vitamin E supplementation was able to improve aminotransferase status of patients with nonalcoholic fatty liver disease (Lavine, 2000) and long-term HCV (Kugelmas et al., 2003) and to decrease the excretion of 8-iso-prostaglandin F 2a in cirrhotic patients (Pratico et al., 1998; Sodergren et al., 2000) . This evidence supported the use of vitamin E therapy (500 mg/die) for the prevention of disease progression in patients with HCV, who follow the ribavirin pharmacological therapy (Ota et al., 2004) . On the other hand, it has also been reported that a-tocopherol failed in preventing hepatocellular carcinoma in patients with liver cirrhosis and positive history of HCV infection (Takagi et al., 2003) . Moreover, Kugelmas et al. (2003) demonstrated that supplementation with 800 IU vitamin E daily dose for 12 weeks in overweight non-alcoholic steatohepatitis patients did not cause statistically significant improvement in liver enzyme levels beyond weight loss alone (Von Herbay et al., 1997) .
The aim of this work was to design a new food able to counteract the oxidative stress accompanying HCV. The use of FSMP is an emerging topic in experimental medicine. FSMP can be developed for the improvement of numerous health-related physiological functions and as adjuvant treatment of chronic diseases (Fogliano and Vitaglione, 2005) . FSMP are supported by increased interest of educated patient groups to natural products and recommended by patients associations, as their use is perceived as more natural and better tolerated than pills or tablets.
Among dietary antioxidants, carotenoids are accumulated in the liver and have a relatively long half-life. They are potent radical scavengers, lycopene being the most effective; therefore, they are promising candidates to improve the antioxidant status of patients with HCV (Vitaglione et al., 2004) .
In this study, an FSMP, designed to afford to HCV patients the highest amount of bioavailable lycopene, was created. A preliminary carotenoid bioavailability study from FSMP in healthy subjects was performed. Data on the use of this antioxidant tomato-based FSMP, as adjuvant in HCV pharmacological treatment, were also provided. A carotenoid bioavailability study and a clinical trial to evaluate the efficacy of 100 g FSMP consumption in association to the pharmacological treatment with pegilated-interferon and ribavirin (PEG-IFN þ RBV), in 39 patients with HCV, were carried out.
Materials and methods

Chemicals
All chemicals and solvents were for high-pressure liquid chromatography (HPLC) or of analytical grade and were purchased from Fluka (Buchs, Switzerland), as were pure b-carotene, pure quercetin, pure a-tocopherol, ethyl b-apo-8 0 -carotenoate (trans) and butyl-hydroxyl toluene (BHT). 2-2 0 -Azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) diammonium salt (ABTS) and 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox) were purchased from Aldrich (Seelze, Germany).
Tomato-based FSMP
The FSMP developed in this study consisted of a concentrated tomato puree added with 10% extra-virgin olive oil. It was produced by the 'Stazione Sperimentale per l'Industria delle Conserve Alimentari' (Angri, Salerno, Italy) using a pilot plant for production of tomato puree.
This plant was deprived of juice refining machine to increase the content of tomato peels, rich of carotenoids. The juice was then evaporated using short temperature (50-601C) and pressure (600-700 mm Hg). When the refractive index of juice was 29-301Brix, the extra-virgin olive oil was added and the tomato puree was heated at 951C for 5 0 . It allowed the homogenization of all components as well as the hot packaging of the product. FSMP was packaged in 200 ml glass cans, pasteurized and cooled. The product had a 'best before' indication of 3 years.
The FSMP was characterized by evaluating physicochemical parameters (refractive index, dry matter and pH), macronutrient contents (fats, carbohydrates and proteins) as well as the concentration of the main bioactive phytochemicals (carotenoids, flavonoids and a-tocopherol).
Physico-chemical parameters. Refractive index and pH values were measured by ATAGO-ACTE 1E refractometer and a HI 9017 microprocessor pH meter (Hanna Instrument, LeightonBuzzard, UK), respectively. Dry matter was evaluated by gravimetric method.
Carotenoid and a-tocopherol. Carotenoids were extracted according to Vitaglione et al. (2002) starting from 4 g FSMP. Samples were stored dried at À201C until the HPLC analysis. The extraction of a-tocopherol from FSMP was carried out according to Bui (1994) with minor modifications. Briefly, the procedure consisted of a basic hydrolysis of sample followed by dichloromethane (DCM) extraction. Samples were stored dried at À201C until the HPLC analysis.
The analytical separation of carotenoid and a-tocopherol extracts was achieved by HPLC connected to an UV-DAD. Dried samples were opportunely diluted in solvent A, and 20 ml were injected onto the column (Develosil 5 mm RP-AQUEOUS C30, 250 Â 4.6 mm -Phenomenex, Torrance, CA, USA). The mobile phase consisted of methanol/water (85:15) added with ammonium acetate 0.004% in water (solvent A) and tert-butyl-methyl-ether (solvent B). The flow rate was 1 ml/min and the following stepwise gradient was used: 0.1 min, 85% A; 5 min, 70% A; 10 min, 60%, from 15 to 35 min, 45% A; 40 min, 20% A; in 5 min column returned to starting conditions and was equilibrated for 5 min before injection.
Identification of the peaks in the HPLC chromatogram of the carotenoid and a-tocopherol extracts was carried out by comparison of UV-VIS spectra and retention times of eluted compounds with pure standards of lycopene, b-carotene, lutein and a-tocopherol. For identification of 5-cis-lycopene, retention times and the rates of absorbance at specific wavelengths, as described by Holloway et al. (2000) , were considered. The carotenoids were quantified at 460 nm using a calibration curve for each carotenoid except for lycopene isomers that were quantified by lycopene-calibration curve. The quantification of a-tocopherol was carried out at 290 nm.
Flavonoids. The determination of quercetin, naringenin and rutin was obtained following the procedure of extraction and quantification for flavonoids proposed by Crozier et al. (1997) .
Antioxidant activity. The FSMP antioxidant activity was measured on carotenoid extracts following the ABTS spectrophotometric method (Pellegrini et al., 1999) . Carotenoid extracts were dissolved in DCM and assayed, making triplicate determinations. Results were expressed as mmol of Trolox necessary to gain the same antioxidant activity, the Trolox equivalent antioxidant capacity.
Human studies Carotenoid bioavailability study in healthy subjects. Eight healthy volunteers (4 M/4 F), mean age 32 years (23-37), mean body mass index 25 (27-30) taking no supplements, drugs or medications, were enrolled for this study. Five subjects (2 M/3 F) consumed 100 g/die of the FSMP for a week whereas the control group was constituted by three volunteers (2 M/1 F) who did not consume the FSMP. All the subjects were non-smokers and signed an informed written consent. Furthermore, during the study, they were allowed to continue their normal dietary habits and their diets were monitored, using a daily dietary consuming schedule, for the FSMP and the helpings of fruits/vegetables eventually consumed.
Blood samples were drawn before (t 0 ), after a week of FSMP administration (t 7 ) and after a week of wash-out (t 14 ). Serum samples obtained by centrifugation of blood samples at 4000 r.p.m for 10 min (41C) were stored at À201C until the analysis.
The carotenoid serum concentration in the blood samples using the method described below was evaluated.
Carotenoid bioavailability study in patients with HCV Patients' enrolment. The characteristics of all the patients enrolled for the carotenoid bioavailability study and for the evaluation of FSMP ability to modulate the efficacy of pharmacological therapy adopted for HCV eradication were summarized in Table 1 .
Thirty-nine (26M/13F) patients with HCV, all treated with PEG-IFN plus RBV with a standard schedule therapy (PEG-IFN 1.5 mg/kg/week þ RBV 1000-1200 mg/die) were enrolled for this study and were randomly assigned into two groups. At baseline, the two groups of patients were similar for the main demographics characteristics (M/F, body weight, age), mean haemoglobin (Hb) concentrations, and both groups received similar mean dose of RBV.
Twenty patients (15M/5F) were asked to consume 100 g of FSMP every day for 6 months in addition to pharmacological treatment (FSMP group), whereas the other 19 patients (11M/8F) did not consume the FSMP (Control group). The treatment with FSMP was approved by the local ethical committee and an informed written consent was signed by all the patients.
After the first tasting, they were asked to answer to an acceptability test of the FSMP. In particular, they had to choose the grade of sensorial acceptance (pleasant, acceptable and unpleasant) of the food relatively to odour, colour, FSMP for patients with HCV infection P Vitaglione et al taste, palatability and consistency as well as to the whole food. Furthermore, during the study they were allowed to continue their dietary habits and their diets were monitored, using a daily dietary consuming schedule, reporting the FSMP and the helpings of fruits/vegetables consumption.
Blood samples were drawn at regular time intervals during the pharmacological treatment period (12 months) and in the follow-up period (6 months after therapy cessation).
Serum samples obtained by centrifugation of blood samples at 4000 r.p.m for 10 min (41C) were stored at À201C until the analysis.
Considering the therapeutic response, patients were classified according to the international convention as Long-term responders (LTR) if they showed a persistent absence of serum HCV-RNA 6 months or more after therapy cessation; Non responders (NR) if they failed to clear their serum from virus during therapy or showed undetectable serum HCV-RNA at the end of therapy but subsequently redeveloped viremia.
Blood sampling. For the carotenoid bioavailability study aimed at evaluating carotenoid and a-tocopherol serum levels, the following time interval blood drawings were monitored: basal time (t 0 ), after 15 days (t 15 ), 1 month (t 1m ), 3 months (t 3m ) and 6 months (t 6m ) from the starting of treatment and after 3 months of follow-up (t 3fu ) for FSMP group patients; for control group patients, the drawings of blood at t 3m and t 3fu were omitted.
Determination of carotenoid and a-tocopherol in the blood. The extraction of serum bioactive compounds was carried out following the procedure reported by Khachik et al. (1997) with minor modifications. Briefly, 1 ml of serum sample was added with 1 ml of ethanol containing 0.1% BHT, was centrifuged at 10000 r.p.m for 10 min and the two phases obtained (the hydroalcoholic one and the protein pellet) were separated. Both the phases were separately extracted with hexane (1 ml) and, after centrifugation at 10000 r.p.m for 10 min, the upper layer (hexane phase) containing serum carotenoids and a-tocopherol was filtered through a Millipore Millex-GN, Bedford, MA, USA (0.22 mm) filter and collected in a glass tube. The extraction with fresh hexane was repeated for three times. The hexane layer collected was then evaporated under nitrogen flow and dissolved in 80 ml chloroform before HPLC analysis. HPLC analysis was achieved using the same procedure previously described for determination of carotenoid and a-tocopherol content in FSMP.
Carotenoids were eluted as follows: lutein, 14 min; a-tocopherol, 20 min; b-carotene, 38 min; 5-cis lycopene, 43 min; all-trans lycopene, 45 min. The peak eluting at 42 min and all the peaks eluting between 18 and 30 min were considered as lycopene-related products and thus quantified to determine total lycopene content (Khachik et al., 1997) .
Evaluation of FSMP efficacy as therapy adjuvant
The efficacy of FSMP as therapy adjuvant was determined through the study of each patient clinical folder. In particular, numerous serum biochemical parameters, such as transaminases (aspartate aminotransferase (AST) and alanine aminotransferase (ALT)), Hb, HCV-RNA, were evaluated.
Moreover the oxidative status of the patients was assessed by measuring, through d-ROM test (Diacron, Italy), serum hydroperoxide concentrations (Verde et al., 2002; Morisco et al., 2004) at the baseline (t 0 ), during therapy (t dt ) and in the follow-up period (t fu ).
Statistical analysis
All determinations were performed in triplicate and the results were presented as mean 7s.d. Comparison of continuous variables were made by either one way, or more, analysis of variances as indicated. The Student's t-test was used for the dichotomous variables as appropriate. A probability of Po0.05 was considered statistically significant.
Results
FSMP physico-chemical and analytical characterization FSMP nutritional facts were reported in Table 2 . FSMP had a total carotenoid content of 23 mg/100 g (about 50% were cis-lycopene isomers), a flavonoid content of 5.3 mg/100 g (corresponding to 0.15 mg/g of dry matter) and an antioxidative activity of 0.21 mmol Trolox/100 g.
Carotenoid bioavailability studies
The preliminary carotenoid bioavailability study in healthy subjects showed that, after a week of 100 g FSMP administration, a fourfold and a twofold increase of baseline serum concentrations of all-trans lycopene (from 0.1670.03 to 0.5070.15 mg/ml corresponding to a range 0.3070.06 to 0.9370.28 mmol/l), and of b-carotene (from 0.1270.09 to 0.2870.17 mg/ml corresponding to a range 0.2270.17 to 0.5270.32 mmol/l), and lutein (from 0.1070.08 to 0.2270.13 mg/ml corresponding to a range 0.1870.14 to 0.3970.23 mmol/l), occurred. On the contrary no significant variation of carotenoid levels in control group patients, at the monitored time intervals, occurred.
The results of carotenoid bioavailability study in patients with HCV were graphically represented in Figure 1 . It showed the concentration of each serum carotenoid in FSMP and Control group subjects at the monitored time intervals. 
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FSMP for patients with HCV infection P Vitaglione et al A significant increase of carotenoid serum concentrations in the patients who had consumed the FSMP in addition to the pharmacological treatment was found.
In particular, after 1 month of FSMP administration (t 1m ) all-trans lycopene, 5-cis lycopene, b-carotene and lutein significantly (Po0.05) increased in patients who did not consume the FSMP by 17, 52, 36 and 17%, in comparison with baseline contents, respectively. On the contrary significant reductions (Po0.05) of 25, 48, 33 and 17% for the same carotenoids were recorded.
Similarly, at t 6m a higher reduction was observed in control group than in FSMP group patients. It is worth noting that the concentration of 5-cis lycopene in patients who consumed the FSMP doubled, at this time, the baseline value.
An increase in 19% of a-tocopherol serum concentration was observed after 1 month of therapy in FSMP group versus a decrease in 24% in control group (Po0.05). Contrary to major carotenoids, vitamin E content always increased during the treatment with FSMP, reaching a significant increase in 13% versus a decrease in 42% in the control group patients after 6 months.
The evaluation of dietary habits of all the patients, obtained through dietary diary, showed no significant differences in fruit and vegetable consumption during the treatment; thus, serum carotenoid variations observed could be correlated only to FSMP consumption.
Evaluation of FSMP efficacy as therapy adjuvant FSMP acceptance. The evaluation of FSMP acceptability tests filled by patients after the first tasting showed a good acceptance of the product. Thirty-five per cent subjects considered the food really pleasant, 42% subjects found it acceptable and 33% did not like it.
Therapeutic response. The evaluation of serum HCV-RNA in patients during the therapy period (12 months) and the follow-up period (6 months after therapy cessation) showed 25/39 LTR patients and 14/39 NR patients. Thirteen out of twenty-five of LTR patients belonged to the FSMP group and 12/25 were in the Control group. Similarly, the 14 NR patients were found equally divided among the FSMP and the Control group (7/14).
Transaminases. Transaminase serum levels at the baseline were higher than the upper limit of the normal range in all the patients. After 6 months of treatment (t 6 ), all the patients normalized their levels whereas after 6 months from therapy cessation (t fu ) transaminase serum levels of NR patients returned to the basal values. As shown in Figure 2 , the variation of AST and ALT serum levels in both LTR and NR patients was independent to the FSMP consumption.
Hydroperoxides. Baseline concentrations of serum hydroperoxides did not differ significantly (P40.05) between the patient group that had consumed the FSMP and the one that did not, being 340761 and 356772 Carr.U., respectively. Moreover hydroperoxide serum levels were almost always higher than the upper limit of the normal range and a significant decrease in comparison with the basal values during the pharmacological treatment of 14 and 15% (291755 and 304759 Carr.U., Po0.05) and in the followup period of 8 and 11% (312744 Carr.U. and 316771 Carr.U., Po0.05) for FSMP and Control group, respectively, was observed. No significant variation between the two groups was recorded (see Figure 3a) .
Looking at the patient therapeutic response (see Figure 3b) , it can be observed that the hydroperoxide serum levels of the LTR patients were in the normal range. On the contrary, the NR group showed that hydroperoxide serum levels were always higher than 300 Carr.U. Nevertheless, in this category of patients, the effect of FSMP was observed. In fact, a significant difference in the reduction of oxidative stress was detectable between the two groups. A 22% reduction of hydroperoxide serum levels in patients who consumed the FSMP (NR-FSMP) versus a 10% reduction (Po0.05) in patients who did not consume the FSMP (NR-C) during the therapy (t dt ), was measured.
Haemoglobin. Hb concentrations were monitored during the first 3 months of therapy and the analysis of results included all the patients who did not modify RBV daily dose during this period (15 and 16 patients belonging to the FSMP and Control group, respectively).
Results showed a reduction trend of serum Hb concentration comparable between the two groups. 
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Considering the whole period of therapy (12 months) in FSMP group, eight patients had to reduce daily RBV dose and only one patient had to suspend it. Similarly, the reduction of daily RBV dose in nine patients belonging to the Control group was necessary because an anaemia status occurred. No difference among LTR and NR patients in both groups was evidenced being these nine patients divided in six and three of the FSMP group and, five and four of the Control group.
Discussion
One-hundred grams of the FSMP described here contained the same quantity of carotenoids of 600 g raw tomatoes.
Moreover, all the steps of FSMP production from the choice of raw materials (tomatoes and extra-virgin olive oil) to the modification of technological process were designed to obtain a highly bioavailable carotenoid-rich tomato-based food. FSMP was produced allowing it to have the highest amount of lycopene cis-isomers and a very accurate dispersion of olive oil in the tomato matrix.
In raw tomatoes, the all-trans lycopene represents the 99% of total lycopene. In the FSMP, the all-trans form was 53% of the total lycopene, 5-cis isomer was the 9% and other cis isomers accounted for the remaining 38%. This finding was in accordance with Schierle et al. (1996) who demonstrated that, in tomato-based products, all-trans and 5-cis lycopene were in the range of 93-35 and 4-27% of total lycopene, respectively.
A major reduction of flavonoids during the process was expected as literature data reported a 80% reduction of these compounds in peeled canned tomato (Stewart et al., 2000) . In the FSMP, the reduction was about 60% (from 0.47 mg/g of dry matter in the raw material to 0.15 mg/g of dry matter in the FSMP). It was due to the exclusion of the juice superrefining filter in the plant, and thus the maintenance of part of the tomato peels (the main site of flavonoids in tomatoes) in the juice.
The antioxidant activity of 0.21 mmol Trolox/100 g was higher than that of a tomato paste having the same dry matter but not added with extra-virgin olive oil (0.13 mmol Trolox/100 g). This result was expected, because the extravirgin olive oil added during the FSMP production showed a high antioxidant activity (0.089 mmol Trolox/100 g), thanks to its high phenolic compound content. Lee et al. (2000) demonstrated that plasma antioxidant activity (measured with FRAP assay) increased after a week's consumption of tomato products added with extra-virgin olive oil but not after the consumption of the same products added with sunflower oil, thanks to olive oil polyphenol content.
Carotenoid bioavailability studies
The results of the preliminary carotenoid bioavailability study demonstrated that the FSMP used in this study was very effective to increase serum lycopene concentration. Although comparing this study with other carotenoid bioavailability studies reported in the literature (Micozzi et al., 1992; Sakamoto et al., 1994; Yeum et al., 1998; Muller et al., 1999; Holloway et al., 2000; Lee et al., 2000; Pellegrini et al., 2000) and summarized in Table 3 , it was evident that FSMP contained a good relative amount of carotenoids and fats. In fact, in many studies, absorption efficiency was shown to decrease as the amount of carotenoids increased (Erdman et al., 1993; Parker, 1996; Furr and Clark, 1997; Castenmiller and West, 1998; Van den Berg et al., 2000) .
On the other hand, data by Pellegrini et al. (2000) suggested that the addition of olive oil to a commercial tomato puree and the heating before the consumption could be very effective to increase lycopene serum concentration.
The results of the bioavailability study in patients with HCV showed a high carotenoid bioavailability from the FSMP also in this category of subjects.
In particular, although the FSMP consumption in HCV patients did not cause an increase of carotenoid serum levels as high as in healthy subjects after only a week of administration, it was able to decrease the antioxidant compound serum depletion caused by chronic disease.
Evaluation of FSMP efficacy as therapy adjuvant
Looking at the therapeutic response, LTR and NR patients were found equally divided in both groups of treatment thus permitting inter-group comparisons of results obtained for all the determinations. In particular, it was demonstrated that the FSMP did not influence AST and ALT serum levels as all patients normalized their values during therapy independently to the FSMP consumption. The finding that serum hydroperoxides in patients enrolled in this study were almost always higher than the upper limit of normal range (250-300 Carr. U.) confirmed the existence of an imbalance in the oxidative homeostasis in patients with HCV and was in accordance with previous findings . In fact, it has been observed that the time course of oxidative status, measured as serum hydroperoxide concentration, in patients with HCV during therapy, is related to the therapeutic response. LTR patients had lower basal serum hydroperoxide concentrations than NR and during the treatment a significant decrease in serum hydroperoxides occurred. LTR patients showed lower hydroperoxide serum levels than NR. During therapy and, in the follow-up period in LTR, but not in NR patients, a reduction of hydroperoxide concentration till the normal range was observed .
In this study the amelioration, during therapy and in the follow-up period, of patient oxidative status (negative trend of serum hydroperoxides) was also related to FSMP consumption. In particular, in NR patients having higher basal hydroperoxide levels, the effect of a highly antioxidant FSMP consumption was demonstrated to be more evident (22% reduction in NR-FSMP versus 10% in NR-C). This finding demonstrated that dietary carotenoids were able to influence oxidative status in patients with HCV who were NRs to pharmaceutical treatment.
Many studies reported that in healthy subjects diets enriched with fat-soluble antioxidants such as lycopene or b-carotene, consumed as pure compounds or in foods, did not affect plasma antioxidant capacity as measured by the hydrophilic TRAP, FRAP, ORAC assays or by ABTS method (Steinberg and Chait, 1998; Bohm and Bitsch, 1999; Bub et al., 2000; Pellegrini et al., 2000) .
Therefore, it can be concluded that the administration of high doses of carotenoids might be able to influence the oxidative status only in the unbalanced situation owing to pathological conditions, such as HCV infection.
FSMP was demonstrated to be ineffective to counteract qthe RBV-related Hb serum levels reduction as anaemia status in all patients occurred independently of the group of treatment.
The whole findings demonstrated that circulating carotenoids after FSMP consumption, although were able to improve total antioxidant status of NR patients, failed to protect red blood cells (RBCs) from RBV-related disruption. This observation was in agreement with the study of Fotouhi et al. (1996) that previously demonstrated that carotenoid concentrations of plasma did not always correlate with the protection of RBCs.
On the other hand, the high grade of FSMP acceptance by patients with HCV (there was no withdrawal from the FSMP-group) was a very important finding, as these patients usually suffer, as side effects of pharmacological treatment, of digestive problems that could alter sensorial sphere and compromise foods choices and dietary lifestyle.
In conclusion, the FSMP developed here was able to counteract carotenoid depletion in patients with HCV, IFN plus RBV treated and proved to be very effective in increasing carotenoid and a-tocopherol concentrations in human plasma.
The evaluation of patients biochemical parameters during the therapy demonstrated that the FSMP consumption did not influence AST, ALT, as well as Hb levels, thus, having no effect in counteracting the anaemia RBV-related and no influence on patient therapeutic responses.
On the other hand, the higher concentration of serum carotenoids due to FSMP consumption contributed to a significant decrease in serum hydroperoxide levels during therapy in the NR patients. This feature demonstrated the ability of FSMP to improve plasma antioxidant status in this category of patients having a severe oxidative imbalance. 
